These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30233215)

  • 1. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
    Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
    Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
    Chang Y; Liu S; Jiang Y; Hua L; Wen L
    Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
    Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
    J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
    Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
    Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
    Chen ZW; Lin G; Shih HJ; Wu CE
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis
    Zhou R; Song L; Zhang W; Shao L; Li X; Li X
    Onco Targets Ther; 2021; 14():2847-2851. PubMed ID: 33958875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.
    Wang Y; Han R; Zhu M; He T; He Y
    Front Oncol; 2022; 12():875313. PubMed ID: 35530305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
    Wang Z; Yang JJ; Huang J; Ye JY; Zhang XC; Tu HY; Han-Zhang H; Wu YL
    J Thorac Oncol; 2017 Nov; 12(11):1723-1727. PubMed ID: 28662863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.
    Chen J; Zhao X; Wang J; Liu F; Zhang L; Chen Y; Chu Q
    Transl Cancer Res; 2022 Sep; 11(9):3343-3348. PubMed ID: 36237272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring
    Ding H; Zhuang Z; Xie J; Huang H; Tao Z; Liu Z
    Onco Targets Ther; 2020; 13():7933-7939. PubMed ID: 32848419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
    Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
    Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
    Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
    Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
    Lin CY; Huang KY; Lin YC; Yang SC; Chung WC; Chang YL; Shih JY; Ho CC; Lin CA; Shih CC; Chang YH; Kao SH; Yang PC
    Cancer Lett; 2021 Jun; 508():76-91. PubMed ID: 33775711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
    Nagasaka M; Balmanoukian AS; Madison R; Zhang SS; Klempner SJ; Ou SI
    Lung Cancer; 2022 Feb; 164():52-55. PubMed ID: 35032819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation
    Lai M; Zhang T; Chen H; Song P; Tong L; Chen J; Liu Y; Ning Y; Feng F; Li Y; Tang H; Chen Y; Fang Y; Lu X; Geng M; Ding K; Yu K; Ding J; Xie H
    J Cancer; 2023; 14(1):152-162. PubMed ID: 36605493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024).
    Das D; Xie L; Hong J
    RSC Med Chem; 2024 Aug; 15(10):3371-94. PubMed ID: 39246743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring
    Chen Y; Hong H; Bao S; Tang H
    Front Pharmacol; 2023; 14():1131703. PubMed ID: 38035001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.